Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.
Genmab A/S
Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.
1 trial -
Acasunlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Genmab A/S
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
1 trial -
Acido Acetilsalicilico Teva Italia 100 mg compresse gastroresistenti, Tora-Dol 30 mg/ml soluzione iniettabile
Fondazione Telethon ETS
Patients scheduled for major surgery for oncologic indication
1 trial -
Active Cannabis
BRIGHT MINDS BIOSCIENCES INC.
Cannabis
1 trial -
Active drug: pimavanserin 17mg (2 strength tablets)
Acadia Pharmaceuticals B.V.
Parkinson Disease
1 trial -
Active rTMS
BRIGHT MINDS BIOSCIENCES INC.
Cannabis Use Disorder
1 trial -
Active smoked cannabis
Camp4 Therapeutics Corp
Cannabis Smoking
1 trial -
Actrapid 100 international units/ml solution for injection in vial, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, SODIUM CHLORIDE, Natriumklorid Fresenius Kabi 9 mg/ml, spädningsvätska för parenteral användning, Albumin Baxalta 200 g/l infusionsvätska, lösning, Glucos Fresenius Kabi 200 mg/ml infusionsvätska, lösning, A24110He
Lacuna Pharma Pty Ltd
Moderate to severe hypertriglyceridemia
1 trial -
Adebellizumab
The First People's Hospital of Lianyungang
Resectable Lung Non-Small Cell Carcinoma
1 trial -
Adebrelimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatic Cancer
1 trial -
Adebrelimab (PD-L1 inhibitor)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatic Cancer Metastatic
1 trial -
Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
Adebrelimab+Albumin paclitaxel +Cisplatin
The First People's Hospital of Lianyungang
Locally Advanced Hypopharyngeal Cancer
1 trial -
Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
The First People's Hospital of Lianyungang
Platinum-sensitive Relapsed Ovarian Cancer
1 trial -
Administration of experimental treatment association (sotorasib, panitumumab 5FU)
NORTHWEST BIOTHERAPEUTICS INC
Colorectal Carcinoma
1 trial -
Aflibercept
Regeneron UK Limited
Proliferative Diabetic Retinopathy
1 trial -
Aglatimagene besadenovec
Candel Therapeutics
Borderline Resectable Pancreatic Adenocarcinoma
1 trial -
Aldesleukin
United Therapeutics Europe Ltd
Type 1 Diabetes
1 trial -
Alirocumab
Regeneron UK Limited
Nephrotic Syndrome
1 trial -
Alirocumab
Regeneron UK Limited
Non Small Cell Lung Cancer
1 trial -
Alirocumab and Cemiplimab
Regeneron UK Limited
Non-small Cell Lung Cancer (NSCLC)
1 trial -
Alnuctamab, Alnuctamab, CC-92480 0.3 mg, CC-92480 0.4 mg, CC-92480 0.6 mg, DEXAMETHASONE, CC-92480 0.2 mg
Celgene Europe Limited
Relapsed and/or Refractory Multiple Myeloma
1 trial -
Alogabat
Hoffmann-La Roche
Angelman Syndrome
1 trial -
Alphagan 2 mg/ml colirio en solución, Brimonidine Tartrate 0.2% w/v Eye Drops., Mirvetuximab Soravtansine, Pred Forte 10 mg/ml colirio en suspensión, Pred Forte 1% w/v, Eye Drops Suspension
AbbVie Deutschland GmbH & Co. KG
Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources